Icon

Xopenex HFA - (EQ 0.045MG BASE/INH; Aerosol, Metered: Inhalation)

Levalbuterol Tartrate Sunovion Pharma
EQ 0.045MG BASE/INH; Aerosol, Metered: Inhalation
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
None None
Indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease.
Yes
****** ** ****** ** ** *** *** **** **** ** **** ****** '***(*** *, ****) *** ************ ********* ** ********. ******* ********** *** ******* **** ****** ********* ** *** ***** ** ***** ****** ******** ** ** ** *** ****. ***** ***** * **** ******* ******** ******** **** ********'* ******* ******* *** ********* *****'* ****** ** ’*** ******, ****** “******* *** ********* ******* ** **********" **** *** ****** ** ***** ** *** ****. ***** ***** *** ******* *** ******* ** *** **********. ******* ***** *** ********** *** ********* ******* ***** *** ******** ***** *** ***** ** ********* *** *** *****. ** ** ********* ** **** **** **** * ********** ******* ** ***** **** ***** *** ****** *** ********** ***** ** ****** **** ***** **** *** **** ****** ** ******* **** *** *****.
Xopenex HFA Patent 1 Patent 2
****** ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ ** *** **, **** ******* **** ******** ** *** *, **** ** **
  1. **** **, **** : ****** ******** ******** ***** *** **** ** *********** ****** '***- *** *, ****.
  2. **** **, **** : ******** **** ****** ** ******** ***** ** ********
  3. *** *, **** : ****** ** ’*** ******, ****** “******* *** ********* ******* ** **********" *** ****** ** *****. *****'* ****** **** *** *** ****** ** *** ********* *** ** ****** ** ** ** ********* ** ****.
  4. *** **, **** : ***** ***** * **** ******* ******** ******* **** ******** ********* *****'* ****** **'***.
  5. *** **, **** : ********** *** ********* **** ****** ********* ** *** ***** ** ***** ****** ******* ******* ** *** *** ******* *** ** *** *, ****.
  6. *** **, **** : ***** **** * ********** ******* ****** **** ** ****** ** *** *** ***** ************ ** ****** ** *****.
  7. *** **, **** : ********** *** ********* ******* ***** *** ******** ***** *** ***** ** ********* *** *** *****.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.